342 related articles for article (PubMed ID: 9599702)
21. Alternative methods for developmental toxicity testing.
Piersma AH
Basic Clin Pharmacol Toxicol; 2006 May; 98(5):427-31. PubMed ID: 16635099
[TBL] [Abstract][Full Text] [Related]
22. CFU-GM assay for evaluation of drug myelotoxic activity.
Pessina A; Bonomi A
Curr Protoc Toxicol; 2007 Nov; Chapter 20():Unit20.2. PubMed ID: 23045143
[TBL] [Abstract][Full Text] [Related]
23. Stem cells in myelotoxicity.
Parent-Massin D; Hymery N; Sibiril Y
Toxicology; 2010 Jan; 267(1-3):112-7. PubMed ID: 19883721
[TBL] [Abstract][Full Text] [Related]
24. An alternative approach for the safety evaluation of new and existing chemicals, an exercise in integrated testing.
Gubbels-van Hal WM; Blaauboer BJ; Barentsen HM; Hoitink MA; Meerts IA; van der Hoeven JC
Regul Toxicol Pharmacol; 2005 Aug; 42(3):284-95. PubMed ID: 15979772
[TBL] [Abstract][Full Text] [Related]
25. Use and validation of HT/HC assays to support 21st century toxicity evaluations.
Patlewicz G; Simon T; Goyak K; Phillips RD; Rowlands JC; Seidel SD; Becker RA
Regul Toxicol Pharmacol; 2013 Mar; 65(2):259-68. PubMed ID: 23291301
[TBL] [Abstract][Full Text] [Related]
26. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening.
O'Brien PJ; Irwin W; Diaz D; Howard-Cofield E; Krejsa CM; Slaughter MR; Gao B; Kaludercic N; Angeline A; Bernardi P; Brain P; Hougham C
Arch Toxicol; 2006 Sep; 80(9):580-604. PubMed ID: 16598496
[TBL] [Abstract][Full Text] [Related]
27. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
[TBL] [Abstract][Full Text] [Related]
28. Current limitations and future opportunities for prediction of DILI from in vitro.
Funk C; Roth A
Arch Toxicol; 2017 Jan; 91(1):131-142. PubMed ID: 27766365
[TBL] [Abstract][Full Text] [Related]
29. Gaining acceptance for the use of in vitro toxicity assays and QIVIVE in regulatory risk assessment.
Meek ME; Lipscomb JC
Toxicology; 2015 Jun; 332():112-23. PubMed ID: 25598226
[TBL] [Abstract][Full Text] [Related]
30. Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies.
Coecke S; Goldberg AM; Allen S; Buzanska L; Calamandrei G; Crofton K; Hareng L; Hartung T; Knaut H; Honegger P; Jacobs M; Lein P; Li A; Mundy W; Owen D; Schneider S; Silbergeld E; Reum T; Trnovec T; Monnet-Tschudi F; Bal-Price A
Environ Health Perspect; 2007 Jun; 115(6):924-31. PubMed ID: 17589601
[TBL] [Abstract][Full Text] [Related]
31. Risk assessment of human myelotoxicity of anticancer drugs: a predictive model and the in vitro colony forming unit granulocyte/macrophage (CFU-GM) assay.
Masubuchi N
Pharmazie; 2006 Feb; 61(2):135-9. PubMed ID: 16526561
[TBL] [Abstract][Full Text] [Related]
32. Validation of Alternative In Vitro Methods to Animal Testing: Concepts, Challenges, Processes and Tools.
Griesinger C; Desprez B; Coecke S; Casey W; Zuang V
Adv Exp Med Biol; 2016; 856():65-132. PubMed ID: 27671720
[TBL] [Abstract][Full Text] [Related]
33. Strengths and limitations of using repeat-dose toxicity studies to predict effects on fertility.
Dent MP
Regul Toxicol Pharmacol; 2007 Aug; 48(3):241-58. PubMed ID: 17512650
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the predictive capacity of the 3T3 Neutral Red Uptake cytotoxicity test method to identify substances not classified for acute oral toxicity (LD50>2000 mg/kg): results of an ECVAM validation study.
Prieto P; Cole T; Curren R; Gibson RM; Liebsch M; Raabe H; Tuomainen AM; Whelan M; Kinsner-Ovaskainen A
Regul Toxicol Pharmacol; 2013 Apr; 65(3):344-65. PubMed ID: 23246604
[TBL] [Abstract][Full Text] [Related]
35. EU research activities in alternative testing strategies: current status and future perspectives.
Vanhaecke T; Snykers S; Rogiers V; Garthoff B; Castell JV; Hengstler JG
Arch Toxicol; 2009 Dec; 83(12):1037-42. PubMed ID: 19908029
[No Abstract] [Full Text] [Related]
36. Stem cells in toxicology: fundamental biology and practical considerations.
Kang KS; Trosko JE
Toxicol Sci; 2011 Mar; 120 Suppl 1():S269-89. PubMed ID: 21163910
[TBL] [Abstract][Full Text] [Related]
37. Biokinetic and toxicodynamic modelling and its role in toxicological research and risk assessment.
Blaauboer BJ
Altern Lab Anim; 2003; 31(3):277-81. PubMed ID: 15612871
[TBL] [Abstract][Full Text] [Related]
38. Validation and development of a predictive paradigm for hemotoxicology using a multifunctional bioluminescence colony-forming proliferation assay.
Rich IN; Hall KM
Toxicol Sci; 2005 Oct; 87(2):427-41. PubMed ID: 16002476
[TBL] [Abstract][Full Text] [Related]
39. Managing hematologic toxicities.
Capo G; Waltzman R
J Support Oncol; 2004; 2(1):65-79. PubMed ID: 15330374
[TBL] [Abstract][Full Text] [Related]
40. Impact of cell types and culture methods on the functionality of in vitro liver systems - A review of cell systems for hepatotoxicity assessment.
Kyffin JA; Sharma P; Leedale J; Colley HE; Murdoch C; Mistry P; Webb SD
Toxicol In Vitro; 2018 Apr; 48():262-275. PubMed ID: 29408671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
